Manages chronic stable angina and angina due to coronary artery spasm. ANDA 216521, held by Sciegen Pharms. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 216521 (Diltiazem Hydrochloride), held by Sciegen Pharms, was first approved by FDA on Sep 23, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 23, 2022 | Original application | Approved | None posted |
| Diltiazem Hydrochloride30MG · tablet;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride60MG · tablet;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride90MG · tablet;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride120MG · tablet;oral | Diltiazem Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters